Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) begin affecting appetite and blood sugar within days to weeks, but clinically meaningful outcomes develop more gradually
How common is it
Explored as a possible aid for recovery and lean-mass preservation in frail or catabolic populations, though a Merck-sponsored Phase 2b trial in elderly hip-fracture patients (Adunsky et al., 2011, Archives of Gerontology and Geriatrics, PMID 21067829) was halted early over a cardiac safety signal rather than demonstrating a clear functional benefit
In 2024 Blue Cross Blue Shield of Michigan informed members and physicians about a change in coverage for GLP-1s.On the surface, GLP-1s promise weight loss, lower blood pressure and a reduced risk of heart and kidney disease, according to the Cleveland Clinic
[PMID: 15357291] PubMed record related to this compound for laboratory literature review
